Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A (Orphanet Journal of Rare Diseases, (2021), 16, 1, (433), 10.1186/s13023-021-02040-8)

Shahram Attarian; Peter Young; Thomas H. Brannagan; David Adams; Philip Van Damme; Florian P. Thomas; Carlos Casanovas; Jafar Kafaie; Céline Tard; Maggie C. Walter; Yann Péréon; David Walk; Amro Stino; Marianne de Visser; Camiel Verhamme; Anthony Amato; Gregory Carter; Laurent Magy; Jeffrey M. Statland; Kevin Felice

doi:10.1186/s13023-024-03110-3

Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A (Orphanet Journal of Rare Diseases, (2021), 16, 1, (433), 10.1186/s13023-021-02040-8)

Shahram Attarian
, Peter Young
, Thomas H. Brannagan
, David Adams
, Philip Van Damme
, Florian P. Thomas
, Carlos Casanovas
, Jafar Kafaie
, Céline Tard
, Maggie C. Walter
, Yann Péréon
, David Walk
, Amro Stino
, Marianne de Visser
, Camiel Verhamme
, Anthony Amato
, Gregory Carter
, Laurent Magy
, Jeffrey M. Statland
, Kevin Felice

School of Medicine

Assistance publique - Hôpitaux de Marseille
Department of Neurology
Columbia University
Assistance publique – Hôpitaux de Paris
KU Leuven
Flanders Institute for Biotechnology
L'Hospitalet de Llobregat
CIBER de Enfermedades Raras (CIBERER)
Saint Louis University
Lille University Hospital
Ludwig Maximilian University of Munich
University Hospital Hotel-Dieu
University of Minnesota Twin Cities
University of Michigan, Ann Arbor
University of Amsterdam
Brigham and Women’s Hospital
Physical Medicine and Rehabilitation
CHU Dupuytren
University of Kansas
Hospital for Special Care New Britain

Research output: Contribution to journal › Comment/debate

Abstract

Following publication of the original article [1], we have been notified that we should add one more author to the authors’ group: Jafar Kafaie 8 8 Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA The original article was updated.

Original language	English
Article number	142
Journal	Orphanet Journal of Rare Diseases
Volume	19
Issue number	1
DOIs	https://doi.org/10.1186/s13023-024-03110-3
State	Published - Dec 2024

Access to Document

10.1186/s13023-024-03110-3

Fingerprint

Dive into the research topics of 'Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A (Orphanet Journal of Rare Diseases, (2021), 16, 1, (433), 10.1186/s13023-021-02040-8)'. Together they form a unique fingerprint.

Cite this

Attarian, S., Young, P., Brannagan, T. H., Adams, D., Van Damme, P., Thomas, F. P., Casanovas, C., Kafaie, J., Tard, C., Walter, M. C., Péréon, Y., Walk, D., Stino, A., de Visser, M., Verhamme, C., Amato, A., Carter, G., Magy, L., Statland, J. M., & Felice, K. (2024). Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A (Orphanet Journal of Rare Diseases, (2021), 16, 1, (433), 10.1186/s13023-021-02040-8). Orphanet Journal of Rare Diseases, 19(1), Article 142. https://doi.org/10.1186/s13023-024-03110-3

@article{e04962897a8f401f8a6422fc8990adb7,

title = "Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot{\textendash}Marie{\textendash}Tooth type 1A (Orphanet Journal of Rare Diseases, (2021), 16, 1, (433), 10.1186/s13023-021-02040-8)",

abstract = "Following publication of the original article [1], we have been notified that we should add one more author to the authors{\textquoteright} group: Jafar Kafaie 8 8 Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA The original article was updated.",

author = "Shahram Attarian and Peter Young and Brannagan, \{Thomas H.\} and David Adams and \{Van Damme\}, Philip and Thomas, \{Florian P.\} and Carlos Casanovas and Jafar Kafaie and C{\'e}line Tard and Walter, \{Maggie C.\} and Yann P{\'e}r{\'e}on and David Walk and Amro Stino and \{de Visser\}, Marianne and Camiel Verhamme and Anthony Amato and Gregory Carter and Laurent Magy and Statland, \{Jeffrey M.\} and Kevin Felice",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

doi = "10.1186/s13023-024-03110-3",

language = "English",

volume = "19",

journal = "Orphanet Journal of Rare Diseases",

issn = "1750-1172",

publisher = "BioMed Central Ltd",

number = "1",

}

Attarian, S, Young, P, Brannagan, TH, Adams, D, Van Damme, P, Thomas, FP, Casanovas, C, Kafaie, J, Tard, C, Walter, MC, Péréon, Y, Walk, D, Stino, A, de Visser, M, Verhamme, C, Amato, A, Carter, G, Magy, L, Statland, JM & Felice, K 2024, 'Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A (Orphanet Journal of Rare Diseases, (2021), 16, 1, (433), 10.1186/s13023-021-02040-8)', Orphanet Journal of Rare Diseases, vol. 19, no. 1, 142. https://doi.org/10.1186/s13023-024-03110-3

Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A (Orphanet Journal of Rare Diseases, (2021), 16, 1, (433), 10.1186/s13023-021-02040-8). / Attarian, Shahram; Young, Peter; Brannagan, Thomas H. et al.
In: Orphanet Journal of Rare Diseases, Vol. 19, No. 1, 142, 12.2024.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A (Orphanet Journal of Rare Diseases, (2021), 16, 1, (433), 10.1186/s13023-021-02040-8)

AU - Attarian, Shahram

AU - Young, Peter

AU - Brannagan, Thomas H.

AU - Adams, David

AU - Van Damme, Philip

AU - Thomas, Florian P.

AU - Casanovas, Carlos

AU - Kafaie, Jafar

AU - Tard, Céline

AU - Walter, Maggie C.

AU - Péréon, Yann

AU - Walk, David

AU - Stino, Amro

AU - de Visser, Marianne

AU - Verhamme, Camiel

AU - Amato, Anthony

AU - Carter, Gregory

AU - Magy, Laurent

AU - Statland, Jeffrey M.

AU - Felice, Kevin

PY - 2024/12

Y1 - 2024/12

N2 - Following publication of the original article [1], we have been notified that we should add one more author to the authors’ group: Jafar Kafaie 8 8 Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA The original article was updated.

AB - Following publication of the original article [1], we have been notified that we should add one more author to the authors’ group: Jafar Kafaie 8 8 Department of Neurology, Saint Louis University School of Medicine, St. Louis, USA The original article was updated.

UR - https://www.scopus.com/pages/publications/85189172663

U2 - 10.1186/s13023-024-03110-3

DO - 10.1186/s13023-024-03110-3

M3 - Comment/debate

C2 - 38561848

AN - SCOPUS:85189172663

SN - 1750-1172

VL - 19

JO - Orphanet Journal of Rare Diseases

JF - Orphanet Journal of Rare Diseases

IS - 1

M1 - 142

ER -

Attarian S, Young P, Brannagan TH, Adams D, Van Damme P, Thomas FP et al. Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A (Orphanet Journal of Rare Diseases, (2021), 16, 1, (433), 10.1186/s13023-021-02040-8). Orphanet Journal of Rare Diseases. 2024 Dec;19(1):142. doi: 10.1186/s13023-024-03110-3

Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A (Orphanet Journal of Rare Diseases, (2021), 16, 1, (433), 10.1186/s13023-021-02040-8)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this